ESMO摘要速遞：科濟藥業CT041 CAR-T治療消化道腫瘤最新進展

全球首創的CLDN18.2 CAR-T細胞藥物被美國FDA授予“孤兒藥”稱號

CARsgen Therapeutics Receives IND Clearance from the NMPA for CT041 CLDN18.2-CAR-T Cells

CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR-T cells Against Solid Tumors without Requiring Preconditioned Lymphodepletion

CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma

科濟生物任命範勇博士擔任全球註冊事務高級副總裁

科濟生物在2019年ASH年會展示CT053治療復發/難治多發性骨髓瘤的臨床研究結果

CARsgen Therapeutics Receives IND Clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody

科濟生物“重組人源化抗Claudin 18.2單克隆抗體注射液”獲NMPA臨床試驗許可

科濟生物CT053細胞治療產品被FDA授予再生醫學先進療法資格